bat science - BAT Science

Research & development at British American Tobacco

Home Page

Whole smoke exposure system
This website is written specifically for scientists with an interest in tobacco-related research or related disciplines. We hope it may also be of interest to members of the public health and regulatory communities.
As a scientist you will be aware that apart from references to journal publications, the material has not been subject to formal external peer review.
For non-scientists there is a summary of our research on our corporate website www.bat.com Opens new window.
David O'Reilly

David O'Reilly PhD
Group Scientific Director


"I believe that tobacco harm reduction has the potential to be one of the biggest public health opportunities of this generation.  Although the proportion of adults who smoke is likely to decline, population growth means that in 10-years time there will likely be as many or more smokers globally as there are today.  We are working towards producing a range of lower-risk products for the millions of adults globally who will continue to consume tobacco and nicotine products.  However, we recognise that the science is complex and that external opinion on tobacco harm reduction continues to be divided.  This is why we have made a long-term commitment to build the science base needed to determine whether new products will pose reduced health risks and to seek the support and guidance of the scientific, public health and regulatory communities in this."

 

British American Tobacco joins the Scientific Advisory Panel of the Institute of In Vitro Sciences (IIVS), USA

IIVS, which was founded in 1997, is a recognized leading provider of in vitro testing in support of toxicological safety evaluations. Rigorous scientific programmes coupled with educational and outreach initiatives have established IIVS Opens new window as a global leader in the advancement of alternatives to animal testing.

The Scientific Advisory Panel is comprised of representatives from companies and organizations eager to promote the use and acceptance of alternative methods to animal testing.

Our programme on in vitro models is detailed below.

In vitro modelling
Disease models

In vitro assessment involves identifying and developing in vitro assays which model pathological processes in key smoking-related diseases. We hope these models will provide us with laboratory based data that the smoke from modified tobacco products may have a reduced biological effect.

Open access

Open access

We continue to publish our scientific research findings in peer reviewed journals. A percentage of these manuscripts are published open access. These manuscripts can be freely downloaded and viewed without subscriptions.

Published papers
Our scientists write many papers which are both accepted and published around the world.
Forthcoming conferences
Discover more about the conferences GR&D will be attending in 2012.